|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current status of diagnosis and treatment of bladder cancer in China-Analyses of Chinese Bladder Cancer Consortium database显示文摘Objective:To investigate current status of diagnosis and treatment of bladder cancer in China.Methods:A database was generated by Chinese Bladder Cancer Consortium(CBCC).From January 2007 to December 2012,14,260 cases from 44 CBCC centers were included.Data of diagnosis,treatment and pathology were collected.Results:The average age was 63.5 year-old and most patients were male(84.3%).The most common histologic types were urothelial carcinoma(91.4%),adenocarcinoma(1.8%),and squamous carcinoma(1.9%).According to 1973 and 2004 WHO grading system,42.0%,41.0%,and 17.0% of patients were grade 1,2,and 3,and 16.0%,48.7%,and 35.3% of patients were papillary urothelial neoplasms of low malignant potential,low,and high grade,respectively.Non-muscle invasive bladder cancer(NMIBC)and muscle invasive bladder cancer(MIBC)were 25.2% and 74.1%,respectively(0.8% not clear).Carcinoma in situ was only 2.4%.Most patients were diagnosed by white-light cystoscopy with biopsy(74.3%).Fluorescence and narrow band imaging cystoscopy had additional detection rate of 1.0% and 4.0%,respectively.Diagnostic transurethral resection(TUR)provided detection rate of 16.9%.Most NMIBCs were treated with TUR(89.2%).After initial TUR,2.6%accepted second TUR,and 45.7%,69.9%,and 58.7% accepted immediate,induced,and maintenance chemotherapy instillation,respectively.Most MIBCs were treated with radical cystectomy(RC,59.7%).Laparoscopic RCs were 35.1%,while open RC 63.4%.Extended and standard pelvic lymph node dissection were 7% and 66%,respectively.Three most common urinary diversions were orthotopic neobladder(44%),ileal conduit(31%),and ureterocutaneostomy(23%).Only 2.3% of patients accepted neo-adjuvant chemotherapy and only 18%of T3 and T4 patients accepted adjuvant chemotherapy.Conclusion:Disease characteristics are similar to international reports,while differences of diagnosis and treatment exist.This study can provide evidences for revisions of the guideline on bladder cancer in China. | Kaiwen Li Tianxin Lin 无 Wei Xue Xin Mu Enci Xu Xu Yang Fubao Chen Guangyong Li Lulin Ma Guoliang Wang Chaozhao Liang Haoqiang Shi Ming Li Mao Tang Xueyi Xue Yisong Lv Yaoliang Deng Chengyang Li Zhiwen Chen Xiaozhou Zhou Fengshuo Jin Xudong Liu Jinxin Wei Lei Shi Xin Gou Weiyang He Liqun Zhou Lin Cai Baiye Jin Guanghou Fu Xiangbo Kong Hongyan Sun Ye Tian Lang Feng Tiejun Pan Yiyi Wu Dongwen Wang Hailong Hao Benkang Shi Yaofeng Zhu Qiang Wei Ping Han Changli Wu Dawei Tian Zhangqun Ye Zheng Liu Zhiping Wang Junqiang Tian Lin Qi Minfeng Chen Wei Li Jinchun Qi Gongxian Wang Longlong Fu Zhaolin Sun Guangheng Luo Zhoujun Shen Zhaowei Zhu Jinchun Xing Zhun Wu Dong Wei Xin Chen Yanqun Na Hongfeng Guo Chunxi Wang Zhihua Lu Chuize Kong Yang Liu Jin Yang Jianyun Hu Xin Gao Jielin Li Changjun Yin Pu Li Shan Chen Zhen Du Jiongming Li Yongji Yan Xu Zhang Shuang Huang Fangjian Zhou Zhiling Zhang Yinghao Sun Shuxiong Zeng Song Cen Jiaquan Zhou Hanzhong Li Jin Wen Jian Huang | 2015 | Asian Journal of Urology2015，2，2： | 21 |
| 2 | Prostate cancer in Asia:A collaborative report显示文摘The incidence of prostate cancer(PCa)within Asian population used to be much lower than in the Western population;however,in recent years the incidence and mortality rate of PCa in some Asian countries have grown rapidly.This collaborative report summarized the latest epidemiology information,risk factors,and racial differences in PCa diagnosis,current status and new trends in surgery management and novel agents for castration-resistant prostate cancer.We believe such information would be helpful in clinical decision making for urologists and oncologists,health-care ministries and medical researchers. | Rui Chen Shancheng Ren 无 Ming Kwong Yiu Ng Chi Fai Wai Sam Cheng Lap Hong Ian Seiji Naito Tadashi Matsuda Elijah Kehinde Ali Kural Jason Yichun Chiu Rainy Umbas Qiang Wei Xiaolei Shi Liqun Zhou Jian Huang Yiran Huang Liping Xie Lulin Ma Changjun Yin Danfeng Xu Kexin Xu Zhangqun Ye Chunxiao Liu Dingwei Ye Xin Gao Qiang Fu Jianquan Hou Jianlin Yuan Dalin He Tiejun Pan Qiang Ding Fengshuo Jin Benkang Shi Gongxian Wang Xiuheng Liu Dongwen Wang Zhoujun Shen Xiangbo Kong Wanhai Xu Yaoliang Deng Haibo Xia Alexa NCohen Xu Gao Chuanliang Xu Yinghao Sun | 2014 | Asian Journal of Urology2014，1，1： | 13 |
| 3 | Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population显示文摘Objective:To evaluate the diagnostic value of fluorescence in situ hybridization(FISH)in bladder cancer.Methods:We enrolled healthy volunteers and patients who were clinically suspected to have bladder cancer and conducted FISH tests and cytology examinations from August 2007 to December 2008.Receiver operating characteristic(ROC)curve analysis was performed and the area under curve(AUC)values were calculated for both the FISH and urine cytology tests.Results:A cohort of 988 healthy volunteers was enrolled to establish a reference range for the normal population.A total of 4807 patients with hematuria were prospectively,randomly enrolled for the simultaneous analysis of urine cytology,FISH testing,and a final diagnosis as determined by the pathologic findings of a biopsy or a surgically-excised specimen.Overall,the sensitivity of FISH in detecting transitional-cell carcinoma was 82.7%,while that of cytology was 33.4%(p<0.001).The sensitivity values of FISH for non-muscle invasive and muscle invasive bladder transitional-cell carcinoma were 81.7%and 89.6%,respectively(p=0.004).The sensitivity values of FISH for low and high grade bladder cancer were 82.6%and 90.1%,respectively(p=0.002).Conclusion:FISH is significantly more sensitive than voided urine cytology for detecting bladder cancer in patients evaluated for gross hematuria at all cancer grades and stages.Higher sensitivity using FISH was obtained in high grade and muscle invasive tumors. | Liqun Zhou Kaiwei Yang Xuesong Li Yi Ding Dawei Mu Hanzhong Li Yong Yan Jinyi Li Dongwen Wang Wei Li Yulong Cong Jiangping Gao Kewei Ma Yajun Xiao Sheng Zhang Hongyi Jiang Weilie Hu Qiang Wei Xunbo Jin Zhichen Guan Qingyong Liu Danfeng Xu Xin Gao Yongguang Jiang Weimin Gan Guang Sun Qing Wang Yanhui Liu Jianquan Hou Liping Xie Xishuang Song Fengshuo Jin Jiafu Feng Ming Cai Zhaozhao Liang Jie Zhang Dingwei Ye Lin Qi Lulin Ma Jianzhong Shou Yuping Dai Jianyong Shao Ye Tian Shizhe Hong Tao Xu Chuize Kong Zefeng Kang Yuexin Liu Xun Qu Benkang Shi Shaobin Zheng Yi Lin Shujie Xia Dong Wei Jianbo Wu Weiling Fu Zhiping Wang Jianbo Liang | 2019 | Asian Journal of Urology2019，6，1： | 2 |
| 4 | Safety and Efficacy of Holmium Laser Resection for Primary Nonmuscle-Invasive Bladder Cancer Versus Transurethral Electroresection: Single-Center Experience显示文摘 | Yaofeng Zhu Xianzhou Jiang Jianping Zhang Weili Chen Benkang Shi Zhishun Xu | 2008 | Urology2008，，3： | 1 |
| 5 | Urodynamic study in the neurogenic bladder dysfunction caused by in- tervertebral disk hernia 显示文摘 | Dong Dexin Xu Zhishun Shi Benkang | 2006 | Neurourol Urodyn2006，25，5： | 1 |
| 6 | Clinical Significance of Intravesical Prostatic Protrusion in Patients with Benign Prostatic Enlargement显示文摘 | Zhang Keqin Xu Zhishun Zhang Jing Wang Haixin Zhang Dongqing Shi Benkang | 2007 | Urology2007，，6： | 1 |
| 7 | Consensus on safety management of novel hormonal therapy for advanced prostate cancer显示文摘Prostate cancer(PCa)is one of the most prevalent malignant tumors in men,accompanied by high incidence and mortality rates.Novel hormonal therapy(NHT)has emerged as the primary treatment for advanced PCa,providing noticeable clinical benefits.However,the diverse range of adverse events(AEs)associated with NHT may influence both treatment efficacy and patients'quality of life.In light of the latest international clinical research evidence and recommendations from domestic and foreign guidelines,this consensus aims to provide a comprehensive overview of the common AEs experienced during NHT for advanced PCa patients.Additionally,it seeks to develop a hierarchical approach to more efficiently manage AEs,presenting valuable insights for clinical medication and adverse reaction management. | Sujun Han Shudong Cheng Degang Ding Jianming Guo Zhisong He Baiye Jin Zhigang Ji Tianxin Lin Yuanjie Niu Weijun Qin Benkang Shi Jinkai Shao Xi'nan Sheng Qiang Wei Xin Wang Xinghuan Wang Shujie Xia Wanhai Xu Qing Zou Xiongbing Zu Renu Eapen Chi‐Fai Ng Hirotsugu Uemura Hiroji Uemura Cheol Kwak Jae Young Joung Marniza Saad Edmund Chiong Nianzeng Xing | 2023 | UroPrecision2023，1，2： | 0 |
| 8 | Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer显示文摘Objective:Real-word data on long-acting luteinizing hormone-releasing hormone(LHRH)agonists in Chinese patients with prostate cancer are limited.This study aimed to determine the real-world effectiveness and safety of the LHRH agonist,goserelin,particularly the long-acting 10.8-mg depot formulation,and the follow-up patterns among Chinese prostate cancer patients.Methods:This was a multicenter,prospective,observational study in hormone treatment-na?ve patients with localized or locally advanced prostate cancer who were prescribed goserelin 10.8-mg depot every 12 weeks or 3.6-mg depot every 4 weeks with or without an anti-androgen.The patients had follow-up evaluations for 26 weeks.The primary outcome was the effectiveness of goserelin in reducing serum testosterone and prostate-specific antigen(PSA)levels.The secondary outcomes included testosterone and PSA levels,attainment of chemical castration(serum testosterone<50 ng/d L),and goserelin safety.The exploratory outcome was the monitoring pattern for serum testosterone and PSA.All analyses were descriptive.Results:Between September 2017 and December 2019,a total of 294 eligible patients received≥1 dose of goserelin;287 patients(97.6%)were treated with goserelin 10.8-mg depot.At week 24±2,the changes from baseline[standard deviation(95%confidence interval)]in serum testosterone(n=99)and PSA(n=131)were-401.0 ng/d L[308.4 ng/d L(-462.5,-339.5 ng/d L)]and-35.4 ng/m L[104.4 ng/m L(-53.5,-17.4 ng/m L)],respectively.Of 112 evaluable patients,100(90.2%)achieved a serum testosterone level<50 ng/d L.Treatment-emergent adverse events(TEAEs)and severe TEAEs occurred in 37.1%and 10.2%of patients,respectively.The mean testing frequency(standard deviation)was 1.6(1.5)for testosterone and 2.2(1.6)for PSA.Conclusions:Goserelin 10.8-mg depot effectively achieved and maintained castration and was well-tolerated in Chinese patients with localized and locally advanced prostate cancer. | Nanhui Chen Zengjun Wang Ming Chen Qi Ma Yi He Yujie Wang Xin Li Mingxing Qiu Lei Shi Shaoxing Zhu Qun Xie Xiuheng Liu Benkang Shi Guowen Lin Weizhong Yang Yongbin Liao Haibin Zhang Shusheng Wang Jiexian Li Shaogang Wang Lijun Dong Hui Chen Jiaju Lu YongyiCheng Xiaoping Zhang Lulin Ma Liqun Zhou He Wang Shen Li Dingwei Ye | 2023 | Cancer Biology & Medicine2023，20，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员